source
- Upcoming FDA decisions in Q3 2026 could signal agency flexibilityThe piece highlights five FDA actions slated for the third quarter of 2026 that industry participants are tracking. Observers say the outcomes may reveal how flexible the agency will be under its…
- House lawmakers hear mixed views on credentialing for psychedelic providersAs psychedelic medicines move closer to market, two members of the U.S. House are outlining how the drugs might be rolled out and what accompanying legislation could look like. The focus of their…